Cancer Monoclonal Antibody Partnering Terms and Agreements
Published: Aug 2014 | Publisher: Current Partnering | Pages: 630SUMMARY
The Cancer Monoclonal Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
TABLE OF CONTENTS
Executive Summary
Chapter 1 Introduction
Chapter 2 Trends in cancer monoclonal antibody dealmaking
2.1. Introduction
2.2. Cancer monoclonal antibody partnering over the years
2.3. Big pharma cancer monoclonal antibody dealmaking activity
2.4. Big biotech cancer monoclonal antibody dealmaking activity
2.5. Most active in cancer monoclonal antibody partnering
2.6. Cancer monoclonal antibody partnering by deal type
2.7. Cancer monoclonal antibody partnering by stage of development
2.8. Cancer monoclonal antibody partnering by cancer indication
2.9. Cancer monoclonal antibody partnering by antibody type
2.10. Disclosed deal terms for cancer monoclonal antibody partnering
2.10.1 Cancer monoclonal antibody partnering headline values
2.10.2 Cancer monoclonal antibody deal upfront payments
2.10.3 Cancer monoclonal antibody deal milestone payments
2.10.4 Cancer monoclonal antibody royalty rates
Chapter 3 Leading cancer monoclonal antibody deals
3.1. Introduction
3.2. Top cancer monoclonal antibody deals by value
Chapter 4 Big pharma cancer monoclonal antibody deals
4.1. Introduction
4.2. How to use big pharma partnering deals
4.3. Big pharma cancer monoclonal antibody partnering company profiles
Abbott
Abbvie
Actavis (formerly called Watson)
Amgen
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chugai Pharmaceutical
CSL
Daiichi Sankyo
Eli Lilly
Fresenius
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Roche
Sanofi
Servier
Takeda
Teva
UCB
Chapter 5 Big biotech cancer monoclonal antibody deals
5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech cancer monoclonal antibody partnering company profiles
Emergent BioSolutions
Genmab
LFB Group
Morphosys
PDL BioPharma
Seattle Genetics
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
Chapter 6 Cancer monoclonal antibody dealmaking directory
6.1. Introduction
6.2. Company A-Z
6.3. By stage of development
Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory
6.4. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
6.5. By oncology therapy area
Oncology
Bone cancer
Brain cancer
Breast cancer
Colorectal cancer
Gastric cancer
Head and neck cancer
Kidney cancer
Leukemia
Acute lymphoblastic leukemia
Acute myelogenous leukemia
Chronic lymphocytic leukemia
Lung cancer
Non small cell lung cancer
Lymphoma
Hodgkin's lymphoma
Non Hodgkin's lymphoma
Melanoma
Metastases
Multiple myeloma
Neuroblastoma
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal cell carcinoma
Solid tumors
Cancer pain
Thyroid cancer
6.6. By monoclonal antibody type
Chapter 7 Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 Deal type definitions
Appendix 2 Example monoclonal antibody cancer partnering agreement
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form Upgrades for subscription access products
Order Form Therapy Reports
Order Form Technology Reports
Table of figures
Figure 1: Cancer monoclonal antibody partnering since 2009
Figure 2: Big pharma top 50 cancer monoclonal antibody deals 2009 to 2014
Figure 3: Big pharma cancer monoclonal antibody deal frequency 2009 to 2014
Figure 4: Big biotech top 50 cancer monoclonal antibody deals 2009 to 2014
Figure 5: Big biotech cancer monoclonal antibody deal frequency 2009 to 2014
Figure 6: Active cancer monoclonal antibody dealmaking activity 2009 to 2014
Figure 7: Cancer monoclonal antibody partnering by deal type since 2009
Figure 8: Cancer monoclonal antibody partnering by stage of development since 2009
Figure 9: Monoclonal antibody partnering by oncology target since 2009
Figure 10: Monoclonal antibody partnering by type since 2009
Figure 11: Cancer monoclonal antibody deals with a headline value by stage of development
Figure 12: Cancer monoclonal antibody deal headline value distribution, US$million discovery stage
Figure 13: Cancer monoclonal antibody deal headline value distribution, US$million preclinical stage
Figure 14: Cancer monoclonal antibody deal headline value distribution, US$million phase I stage
Figure 15: Cancer monoclonal antibody deal headline value distribution, US$million phase II stage
Figure 16: Cancer monoclonal antibody deal headline value distribution, US$million phase III stage
Figure 17: Cancer monoclonal antibody deal headline value distribution, US$million regulatory stage
Figure 18: Cancer monoclonal antibody deal headline value distribution, US$million marketed stage
Figure 19: Cancer monoclonal antibody deal headline value median value by stage of development
Figure 20: Cancer monoclonal antibody deals with upfront payment values by stage of development
Figure 21: Cancer monoclonal antibody deal upfront distribution, US$million discovery stage
Figure 22: Cancer monoclonal antibody deal upfront value distribution, US$million preclinical stage
Figure 23: Cancer monoclonal antibody deal upfront value distribution, US$million phase I stage
Figure 24: Cancer monoclonal antibody deal upfront value distribution, US$million phase II stage
Figure 25: Cancer monoclonal antibody deal upfront value distribution, US$million phase III stage
Figure 26: Cancer monoclonal antibody deal upfront value distribution, US$million regulatory stage
Figure 27: Cancer monoclonal antibody deal upfront value distribution, US$million marketed stage
Figure 28: Cancer monoclonal antibody deal upfront value median value by stage of development
Figure 29: Cancer monoclonal antibody deals with milestone payment by stage of development
Figure 30: Cancer monoclonal antibody deal milestone distribution, US$million discovery stage
Figure 31: Cancer monoclonal antibody deal milestone value distribution, US$million preclinical stage
Figure 32: Cancer monoclonal antibody deal milestone value distribution, US$million phase I stage
Figure 33: Cancer monoclonal antibody deal milestone value distribution, US$million phase II stage
Figure 34: Cancer monoclonal antibody deal milestone value distribution, US$million phase III stage
Figure 35: Cancer monoclonal antibody deal milestone value distribution, US$million regulatory stage
Figure 36: Cancer monoclonal antibody deal milestone value distribution, US$million marketed stage
Figure 37: Cancer monoclonal antibody deals with royalty rates
Figure 38: Cancer monoclonal antibody deal royalty rate distribution, US$million discovery stage
Figure 39: Cancer monoclonal antibody deal royalty rate value distribution, US$million preclinical stage
Figure 40: Cancer monoclonal antibody deal royalty rate value distribution, US$million phase I stage
Figure 41: Cancer monoclonal antibody deal royalty rate value distribution, US$million phase II stage
Figure 42: Cancer monoclonal antibody deal royalty rate value distribution, US$million phase III stage
Figure 43: Cancer monoclonal antibody deal royalty rate value distribution, US$million regulatory stage
Figure 44: Cance monoclonal antibody deal royalty rate value distribution, US$million marketed stage
Figure 45: Cancer monoclonal antibody deal royalty value median value by stage of development
Figure 46: Top cancer monoclonal antibody deals by value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events
Figure 49: Deal type definitions
Figure 50: Collaborative R&D agreement for BiTE antibodies against three undisclosed solid tumor targets
Chapter 1 Introduction
Chapter 2 Trends in cancer monoclonal antibody dealmaking
2.1. Introduction
2.2. Cancer monoclonal antibody partnering over the years
2.3. Big pharma cancer monoclonal antibody dealmaking activity
2.4. Big biotech cancer monoclonal antibody dealmaking activity
2.5. Most active in cancer monoclonal antibody partnering
2.6. Cancer monoclonal antibody partnering by deal type
2.7. Cancer monoclonal antibody partnering by stage of development
2.8. Cancer monoclonal antibody partnering by cancer indication
2.9. Cancer monoclonal antibody partnering by antibody type
2.10. Disclosed deal terms for cancer monoclonal antibody partnering
2.10.1 Cancer monoclonal antibody partnering headline values
2.10.2 Cancer monoclonal antibody deal upfront payments
2.10.3 Cancer monoclonal antibody deal milestone payments
2.10.4 Cancer monoclonal antibody royalty rates
Chapter 3 Leading cancer monoclonal antibody deals
3.1. Introduction
3.2. Top cancer monoclonal antibody deals by value
Chapter 4 Big pharma cancer monoclonal antibody deals
4.1. Introduction
4.2. How to use big pharma partnering deals
4.3. Big pharma cancer monoclonal antibody partnering company profiles
Abbott
Abbvie
Actavis (formerly called Watson)
Amgen
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chugai Pharmaceutical
CSL
Daiichi Sankyo
Eli Lilly
Fresenius
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Roche
Sanofi
Servier
Takeda
Teva
UCB
Chapter 5 Big biotech cancer monoclonal antibody deals
5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech cancer monoclonal antibody partnering company profiles
Emergent BioSolutions
Genmab
LFB Group
Morphosys
PDL BioPharma
Seattle Genetics
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
Chapter 6 Cancer monoclonal antibody dealmaking directory
6.1. Introduction
6.2. Company A-Z
6.3. By stage of development
Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory
6.4. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
6.5. By oncology therapy area
Oncology
Bone cancer
Brain cancer
Breast cancer
Colorectal cancer
Gastric cancer
Head and neck cancer
Kidney cancer
Leukemia
Acute lymphoblastic leukemia
Acute myelogenous leukemia
Chronic lymphocytic leukemia
Lung cancer
Non small cell lung cancer
Lymphoma
Hodgkin's lymphoma
Non Hodgkin's lymphoma
Melanoma
Metastases
Multiple myeloma
Neuroblastoma
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal cell carcinoma
Solid tumors
Cancer pain
Thyroid cancer
6.6. By monoclonal antibody type
Chapter 7 Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 Deal type definitions
Appendix 2 Example monoclonal antibody cancer partnering agreement
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form Upgrades for subscription access products
Order Form Therapy Reports
Order Form Technology Reports
Table of figures
Figure 1: Cancer monoclonal antibody partnering since 2009
Figure 2: Big pharma top 50 cancer monoclonal antibody deals 2009 to 2014
Figure 3: Big pharma cancer monoclonal antibody deal frequency 2009 to 2014
Figure 4: Big biotech top 50 cancer monoclonal antibody deals 2009 to 2014
Figure 5: Big biotech cancer monoclonal antibody deal frequency 2009 to 2014
Figure 6: Active cancer monoclonal antibody dealmaking activity 2009 to 2014
Figure 7: Cancer monoclonal antibody partnering by deal type since 2009
Figure 8: Cancer monoclonal antibody partnering by stage of development since 2009
Figure 9: Monoclonal antibody partnering by oncology target since 2009
Figure 10: Monoclonal antibody partnering by type since 2009
Figure 11: Cancer monoclonal antibody deals with a headline value by stage of development
Figure 12: Cancer monoclonal antibody deal headline value distribution, US$million discovery stage
Figure 13: Cancer monoclonal antibody deal headline value distribution, US$million preclinical stage
Figure 14: Cancer monoclonal antibody deal headline value distribution, US$million phase I stage
Figure 15: Cancer monoclonal antibody deal headline value distribution, US$million phase II stage
Figure 16: Cancer monoclonal antibody deal headline value distribution, US$million phase III stage
Figure 17: Cancer monoclonal antibody deal headline value distribution, US$million regulatory stage
Figure 18: Cancer monoclonal antibody deal headline value distribution, US$million marketed stage
Figure 19: Cancer monoclonal antibody deal headline value median value by stage of development
Figure 20: Cancer monoclonal antibody deals with upfront payment values by stage of development
Figure 21: Cancer monoclonal antibody deal upfront distribution, US$million discovery stage
Figure 22: Cancer monoclonal antibody deal upfront value distribution, US$million preclinical stage
Figure 23: Cancer monoclonal antibody deal upfront value distribution, US$million phase I stage
Figure 24: Cancer monoclonal antibody deal upfront value distribution, US$million phase II stage
Figure 25: Cancer monoclonal antibody deal upfront value distribution, US$million phase III stage
Figure 26: Cancer monoclonal antibody deal upfront value distribution, US$million regulatory stage
Figure 27: Cancer monoclonal antibody deal upfront value distribution, US$million marketed stage
Figure 28: Cancer monoclonal antibody deal upfront value median value by stage of development
Figure 29: Cancer monoclonal antibody deals with milestone payment by stage of development
Figure 30: Cancer monoclonal antibody deal milestone distribution, US$million discovery stage
Figure 31: Cancer monoclonal antibody deal milestone value distribution, US$million preclinical stage
Figure 32: Cancer monoclonal antibody deal milestone value distribution, US$million phase I stage
Figure 33: Cancer monoclonal antibody deal milestone value distribution, US$million phase II stage
Figure 34: Cancer monoclonal antibody deal milestone value distribution, US$million phase III stage
Figure 35: Cancer monoclonal antibody deal milestone value distribution, US$million regulatory stage
Figure 36: Cancer monoclonal antibody deal milestone value distribution, US$million marketed stage
Figure 37: Cancer monoclonal antibody deals with royalty rates
Figure 38: Cancer monoclonal antibody deal royalty rate distribution, US$million discovery stage
Figure 39: Cancer monoclonal antibody deal royalty rate value distribution, US$million preclinical stage
Figure 40: Cancer monoclonal antibody deal royalty rate value distribution, US$million phase I stage
Figure 41: Cancer monoclonal antibody deal royalty rate value distribution, US$million phase II stage
Figure 42: Cancer monoclonal antibody deal royalty rate value distribution, US$million phase III stage
Figure 43: Cancer monoclonal antibody deal royalty rate value distribution, US$million regulatory stage
Figure 44: Cance monoclonal antibody deal royalty rate value distribution, US$million marketed stage
Figure 45: Cancer monoclonal antibody deal royalty value median value by stage of development
Figure 46: Top cancer monoclonal antibody deals by value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events
Figure 49: Deal type definitions
Figure 50: Collaborative R&D agreement for BiTE antibodies against three undisclosed solid tumor targets
$1,995
My Basket
 | Actelion Partnering 2009-2014 | $995 |
| Transdermal Drug Delivery Partnering 2009-2014 | $995 |
| TOTAL | $1,990 | |
| Empty Cart | ||
| ||
Need Help?
Unsure which report to purchase or have a query regarding a report, please contact us and we'll be glad to help.
Contact our Report Store Team
Email us or call
+44 (0)1904 435190 Europe
+1 (813) 971.8273 US
- Most Viewed